

## **AAM's Biosimilars Council Praises House Passage of the FDA Reauthorization Act of 2017**

WASHINGTON, DC (July 12, 2017) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), issued the following statement regarding the U.S. House of Representative's passage of the FDA Reauthorization Act of 2017:

“With today's vote, the House has taken an important step toward bringing more life-saving biosimilar medicines to market over the next five years at a savings over expensive biologics,” said Biosimilars Council Executive Director Christine Simmon. “This bill will help increase competition, ensuring that patients will have more timely access to safe, effective and affordable biosimilar medicines.”

The Generic Pharmaceutical Association (GPhA) is now AAM.

[Read the Letter of Support](#)

### **About AAM**

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person's life and the world around them. Generic and biosimilar medicines improve people's lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 89 percent of prescriptions dispensed in the U.S. but only 27 percent of total drug spending. Additional information is available at [www.accessiblemeds.org](http://www.accessiblemeds.org).

### **About the AAM Biosimilars Council**

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at [www.biosimilarscouncil.org](http://www.biosimilarscouncil.org).